Overall, treatment with GLP-1 or dual GLP-1/GIP receptor agonists was associated with a substantial reduction in the risk of multiple biliary complications, including cholelithiasis, cholecystitis, and choledocholithiasis, without increasing the risk of cholangitis. This evidence concerns the gene GCG and choledocholithiasis.